223671-87-2

Usage

Uses

Used in Pharmaceutical Industry:
7-Bromo-4-chloroisoquinolin-1(2H)-one is used as a building block in the synthesis of various pharmaceutical drugs and agrochemicals. Its unique chemical structure allows for the development of new and effective therapeutic agents.
Used in Research:
7-Bromo-4-chloroisoquinolin-1(2H)-one is used as a research chemical for the study of various biological processes. Its potential pharmacological activities make it a valuable tool for understanding the mechanisms of action of different drugs and their interactions with biological systems.
Used as a Precursor:
7-Bromo-4-chloroisoquinolin-1(2H)-one is used as a precursor in the synthesis of complex organic molecules. Its versatile chemical properties enable the creation of a wide range of compounds with diverse applications in various fields.
Used in Therapeutic Potential Exploration:
7-Bromo-4-chloroisoquinolin-1(2H)-one exhibits potential pharmacological activities and is being explored for its therapeutic potential in various disease conditions. Its unique structure and properties make it a promising candidate for the development of new treatments and therapies.

InChI:InChI=1/C9H5BrClNO/c10-5-1-2-6-7(3-5)9(13)12-4-8(6)11/h1-4H,(H,12,13)

Upstream product

• 223671-15-6 7-bromo-1(2H)-isoquinolone 
• 223671-15-6 7-bromo-1-hydroxyisoquinoline 

Downstream Products

• 223671-88-3 4-chloro-7-(phenylsulfanyl)-1(2H)-isoquinolone 

Relevant academic research and scientific papers

Cell-Active Small Molecule Inhibitors of the DNA-Damage Repair Enzyme Poly(ADP-ribose) Glycohydrolase (PARG): Discovery and Optimization of Orally Bioavailable Quinazolinedione Sulfonamides

DNA damage repair enzymes are promising targets in the development of new therapeutic agents for a wide range of cancers and potentially other diseases. The enzyme poly(ADP-ribose) glycohydrolase (PARG) plays a pivotal role in the regulation of DNA repair mechanisms; however, the lack of potent drug-like inhibitors for use in cellular and in vivo models has limited the investigation of its potential as a novel therapeutic target. Using the crystal structure of human PARG in complex with the weakly active and cytotoxic anthraquinone 8a, novel quinazolinedione sulfonamides PARG inhibitors have been identified by means of structure-based virtual screening and library design. 1-Oxetan-3-ylmethyl derivatives 33d and 35d were selected for preliminary investigations in vivo. X-ray crystal structures help rationalize the observed structure-activity relationships of these novel inhibitors.

2,4-DIOXO-QUINAZOLINE-6-SULFONAMIDE DERIVATIVES AS INHIBITORS OF PARG

The present invention relates to compounds of formula I that function as inhibitors of PARG (Poly ADP-ribose glycohydrolase) enzyme activity wherein R1a, R1b, R1c, R1d, R1e, W, X1, X2, X3, X4, X5, X6, X7, c are each as defined herein. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative disorders, such as cancer, as well as other diseases or conditions in which PARG activity is implicated.

6,6-FUSED BICYCLIC AROMATIC COMPOUNDS AND THEIR THERAPEUTI USE

This invention relates to a class of 6,6-fused bicyclic aromatic compounds which are ligands of the CRTH2 receptor (Chemoattractant Receptor-homologous molecule expressed on T Helper cells type 2), and their use in the treatment of diseases responsive to

Composition for the treatment of damaged tissue

A pharmaceutical for use in damaged tissue, such as wound, treatment (e.g. healing) is described. The pharmaceutical comprising a composition which comprises: (a) a growth factor; and (b) an inhibitor agent; and optionally (c) a pharmaceutically acceptable carrier, diluent or excipient; wherein the inhibitor agent can inhibit the action of at least one specific adverse protein (e.g. a specific protease) that is upregulated in a damaged tissue, such as a wound, environment.

Isoquinolines as urokinase inhibitors

Compounds of formula (I): and pharmaceutically acceptable salts thereof, wherein one of R1 and R2 is H and the other is N=C(NH2)2 or NHC(=NH)NH2, and the other substituents are as defined herein, are urokinase (uPA) inhibitors.

Isoquinolines

Isoquinolinylguanidine compounds of formula (I): STR1 wherein the substituents are as defined herein, and salts thereof, are disclosed as urokinase inhibitors.